文献速递新发突发、热带与寄生虫病

剖析CYD-TDV登革热疫苗在初治与登革热暴露个体中诱导的抗体

Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
PubMed 文献 · J Infect Dis · 2017-01-01

该研究比较了未感染过登革病毒(DENV)与既往感染过DENV的个体接种赛诺菲巴斯德四价登革热减毒活疫苗(CYD-TDV)后诱导的中和抗体特性。研究发现,初治个体可对所有4种血清型产生中和抗体,其中DENV4主要由型特异性抗体中和,而DENV1、DENV2和DENV3主要由血清型交叉反应抗体中和。既往免疫个体接种后产生更高水平的中和抗体,且CYD-TDV可提升交叉反应中和抗体同时维持接种前获得的型特异性中和抗体。

要点

  • 初治个体接种CYD-TDV后可产生针对全部4种DENV血清型的中和抗体。
  • DENV4主要由型特异性抗体中和,DENV1-3主要由交叉反应抗体中和。
  • 既往登革热免疫者接种后中和抗体水平高于初治接种者。

核心结论

  • CYD-TDV诱导的中和抗体质量因DENV血清型和既往登革热免疫状态而异。

研究设计与样本

  • 研究比较了未感染过DENV与既往感染过DENV的CYD-TDV接种者血清中抗体的特性。
  • 通过耗竭免疫血清中特定DENV反应性抗体群来评估血清型交叉反应和型特异性抗体对中和作用的贡献。

主要发现

  • 无既往DENV免疫的受试者产生了针对全部4种DENV血清型的中和抗体。
  • DENV4主要由型特异性抗体中和,而DENV1、DENV2和DENV3主要由血清型交叉反应抗体中和。
  • 既往DENV免疫者接种后产生的中和抗体水平高于初治接种者。
  • 既往免疫者接种CYD-TDV提升了交叉反应中和抗体,同时维持了接种前已获得的型特异性中和抗体。

临床怎么用

  • 解读CYD-TDV效力时需考虑血清型和接种前登革热免疫状态对中和抗体质量的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sanofi Pasteur has developed a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) that is currently approved for use in several countries. In clinical trials, CYD-TDV was efficacious at reducing laboratory-confirmed cases of dengue disease. Efficacy varied by dengue virus (DENV) serotype and prevaccination dengue immune status. We compared the properties of antibodies in naive and DENV-exposed individuals who received CYD-TDV. We depleted specific populations of DENV-reactive antibodies from immune serum samples to estimate the contribution of serotype-cross-reactive and type-specific antibodies to neutralization. Subjects with no preexisting immunity to DENV developed neutralizing antibodies to all 4 serotypes of DENV. Further analysis demonstrated that DENV4 was mainly neutralized by type-specific antibodies whereas DENV1, DENV2, and DENV3 were mainly neutralized by serotype cross-reactive antibodies. When subjects with preexisting immunity to DENV were vaccinated, they developed higher levels of neutralizing antibodies than naive subjects who were vaccinated. In preimmune subjects, CYD-TDV boosted cross-reactive neutralizing antibodies while maintaining type-specific neutralizing antibodies acquired before vaccination. Our results demonstrate that the quality of neutralizing antibodies induced by CYD-TDV varies depending on DENV serotype and previous immune status. We discuss the implications of these results for understanding vaccine efficacy.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Henein S, Swanstrom J, Byers AM, et al. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals. J Infect Dis. 2017. PMID: 27932620. doi:10.1093/infdis/jiw576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。